Investors hazy over US NDA submission by Affymax, Takeda for anaemia drug
This article was originally published in Scrip
Executive Summary
Investors were having trouble making up their minds on 31 May about whether Affymax's and Takeda Pharmaceutical's new drug application (NDA) submission to the US FDA for the firms' investigational agent peginesatide, formerly known as Hematide, was finally a happy turn of events or maybe not so much.